GERN - Geron Corporation

GERN - Geron Corporation

https://www.geron.com

Buy Momentum: Bearish

Recent News

Powered by Alpha Vantage

GERON ( GERN ) ALERT: Bragar Eagel & Squire, P.C. is Investigating Geron Corporation on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm - Geron ( NASDAQ:GERN )

Benzinga • 1 month ago • score: 0.05

NEW YORK, Aug. 13, 2025 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Geron Corporation GERN on behalf of long-term stockholders following a class action complaint that was filed against Geron on ...

Geron ( GERN ) Reports Q2 Loss, Tops Revenue Estimates

Zacks Commentary • 1 month, 1 week ago • score: 0.04

Geron (GERN) delivered earnings and revenue surprises of +33.33% and +2.35%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

GERON ALERT: Bragar Eagel & Squire, P.C. is Investigating Geron Corporation on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm - Geron ( NASDAQ:GERN )

Benzinga • 3 months, 4 weeks ago • score: 0.05

NEW YORK, May 15, 2025 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Geron Corporation GERN on behalf of long-term stockholders following a class action complaint that was filed against Geron on ...

The Gross Law Firm Notifies Shareholders of Geron Corporation ( GERN ) of a Class Action Lawsuit and an Upcoming Deadline - Geron ( NASDAQ:GERN )

Benzinga • 4 months ago • score: 0.01

NEW YORK, May 12, 2025 ( GLOBE NEWSWIRE ) -- The Gross Law Firm issues the following notice to shareholders of Geron Corporation GERN. Shareholders who purchased shares of GERN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

Faruqi & Faruqi Reminds Geron Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 12, 2025 - GERN - Geron ( NASDAQ:GERN )

Benzinga • 4 months ago • score: 0.13

Faruqi & Faruqi, LLP Securities Litigation Partner James ( Josh ) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Geron To Contact Him Directly To Discuss Their Options

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of May 12, 2025 in Geron Corporation Lawsuit - GERN

Business Insider • 4 months ago • score: -0.17

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of May 12, 2025 in Geron Corporation Lawsuit ...

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

As of 2025-09-10 (Snapshot)

Geron Corporation, an advanced stage clinical biopharmaceutical company, focuses on the development and commercialization of therapies for myeloid hematologic neoplasms. The company is headquartered in Foster City, California.

52W High

$4.83

52W Low

$1.09

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

0.63

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-9.06

EV/Revenue (<3 favorable)

3.81

P/S (TTM) (<3 favorable)

5.43

P/B (<3 favorable)

3.44

Ownership

Institution‑heavy

Source: Overview

Insiders (1–5% typical)

0.09%

Institutions (25–75% balanced)

81.97%

Shares Outstanding

638,017,000

Float

534,078,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

164,447,000

Gross Profit (TTM)

80,412,000

EPS (TTM)

-0.13

Profit Margin (>10% good)

-0.54%

Operating Margin (TTM) (higher better)

-0.25%

ROE (TTM) (>15% strong)

-0.31%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

54.60

Momentum

Bearish momentum

Value

0.0233

Previous

0.0267

Trend

Falling

Signal Cross

No cross

As of

Sep. 05, 2025